ORAL Walking
| Medication
|
Ampyra by: Biogen Idec, approved in 2013.
(Twice a day pill)
"is the
only prescription medicine indicated to help improve walking in adults
with MS" **This is NOT a disease modifying drug**
| https://ampyra.com/
|
ORAL
| Medication |
Aubagio -by: Sanofi Genzyme, approved in 2012.
"Is approved by FDA to treat relapsing forms of MS."
| www.aubagio.com/
|
Gilenya by: Norvartis, approved in 2010.
(A once a day oral pill)
"Is a prescription medication use to treat relapsing forms of MS."
| www.gilenya.com/index.jsp
For kids 10-17 years old
www.gilenya.com/multiple-sclerosis/treatment-results-children
|
Mavenclad by: EMD Serono, approved in 2019
(oral medication that is given in only two annual courses for a maximum
of 20 days over a period of two years. No additional treatments are
needed for the next two years)
"is used to treat relapsing
forms of multiple sclerosis (MS), to include relapsing-remitting disease
and active secondary progressive disease, in adults." | www.mavenclad.com/en/now-approved |
Mayzent by: Norvartis, approved in 2019. (Patient receive a starter pack of tablets that gradually increases the daily dose over 5 days) "is the first treatment
specifically approved for patients with active secondary progressive
multiple sclerosis (SPMS) in over 15 years[1]" and relapsing MS. | |
Ponvory by: Janssen approved in 2021
(A daily oral pill)
"approved by the FDA for the treatment of people with relapsing forms of MS" | www.janssen.com/janssen-announces-us-fda-approval-ponvory-ponesimod-oral-treatment-adults-relapsing-multiple
|
Tecfidera by: Biogen Idec, approved in 2013.
(A daily oral pill)
"approved by the FDA for the treatment of people with relapsing forms of MS" | www.tecfidera.com/ |
Vumerity by: Biogen, approved in 2019.
(Twice a day pill)
"is indicated for the treatment of relapsing forms of multiple sclerosis
(MS), to include clinically isolated syndrome, relapsing-remitting
disease, and active secondary progressive disease, in adults" | www.vumerity.com/en_us/home.html
|
Zeposia by: Bristol Myers approved in 2020.
(A once a day oral pill)
The FDA approved ozanimod, which will carry the brand name Zeposia, for the treatment of relapsing MS. | www.zeposia.com/multiple-sclerosis/
www.zeposia.com/
|
| INJECTABLE | Medication |
Avonex -by: Avonex,approved in 1996.
(A once a week injection-intramuscular)
"Is approved by FDA to treat relapsing forms of MS."
|
https://www.avonex.com/
|
Betaseron by: Bayer, approved in 1993.
(A every other day injection-subcutaneously)
"Is indicated for patients with clinically isolated syndrome (CIS)
and have MRI features consistent with MS as well as
Relapsing-Remitting MS."
|
www.betaseron.com
|
Copaxone by: Teva, approved in 1996.
(*40mg three day per week injection-subcutaneously. *20mg A daily injection-subcutaneously)
"Is indicated for the reduction of the
frequency of relapses in relapsing-remitting MS,
including patients who have experienced a first clinical episode and
have MRI features consistent with MS."
|
www.copaxone.com/ |
Extavia by: Norvartis, approved in 2009.
(A every other day injection-subcutaneously)
"Is a prescription medication approved for the treatment of relapsing forms of MS." | www.extavia.com |
Glatiramer Acetate by: Mylan, approved in 2018.
(40 mg three times per week injection subcutaneously)
"indicated for the treatment of patients with relapsing-forms of multiple sclerosis. generic equivalent of
Copaxone" *Generic Drug* | www.glatirameracetate.com/
|
Glatopa by: Sandoz, approved in 2015.
(20mg daily and 40 three times per week injection-subcutaneously)
"is indicated for the treatment of patients with relapsing-forms of multiple sclerosis. generic equivalent of
Copaxone 20mg dose" *Generic Drug*
| http://glatopa.com/
|
Plegridy by: Biogen Idec, approved in 2014.
(A bi-weekly injection-subcutaneously)
"Is approved by FDA to treat the long-term treatment of relapsing forms of MS." | www.plegridy.com/
|
Rebif by: EMD Serono, approved in 2002.
(A three day per week injection-subcutaneously)
"Is a prescription medication use to treat relapsing forms of MS." | www.rebif.com |
| INFUSION (IV) | Medication |
Lemtrada by: Genzyme, approved in 2014.
(First Treatment: 12 mg/day on 5 consecutive days (60 mg total
dose). Second Treatment: 12 mg/day on 3 consecutive days
(36 mg total dose) administered 12months after the first treatment
course.)
"is indicated for the treatment of patients with relapsing forms
of multiple sclerosis (MS). Because of its safety profile,and
should generally be reserved for patients who have had an inadequate
response to two or more drugs indicated for the treatment of MS." | |
Novantrone by: Suboxone, approved in 2002.
(A infusion (IV) therapy)
"An immunosuppressant that is
approved for use in patients with worsening RRMS, AND is the only approved disease modifying drug for secondary-progressive
MS, or progressive-relapsing MS." | www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/treatments/medications/mitoxantrone/index.aspx |
Ocrevus by: Genentech, approved in 2017
(A infusion (IV) therapy)
"is a prescription medicine used to treat adults with relapsing or primary progressive forms of multiple sclerosis" | https://ocrevusevents.com/
|
Tysabri by: Biogen Idec, approved in 2006.
(A infusion (IV) therapy given once every four weeks)
"Is a prescription medication approved for adult patients with relapsing forms of MS." |
www.tysabri.com
|